Ondine Biomedical Enters $50B Global ICU Anti-Infectives Market
Ondine Biomedical has announced its entry into the $50 billion global ICU anti-infectives market with its Steriwave nasal photodisinfection therapy, following promising study results from the Royal Columbian Hospital in Canada. The ICU pilot study showed that Steriwave achieved an 80% relative risk reduction in pathogen colonisation — a fourfold reduction compared to controls. ICU-acquired…
